Last reviewed · How we verify
Cisplatin（adjuvant）
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and triggering cancer cell death.
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and triggering cancer cell death. Used for Adjuvant chemotherapy for various solid tumors (specific indication depends on cancer type and clinical context).
At a glance
| Generic name | Cisplatin（adjuvant） |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which inhibit DNA synthesis and transcription. This leads to apoptosis in rapidly dividing cancer cells. As an adjuvant therapy, it is used after primary treatment (surgery or radiation) to eliminate residual disease and reduce recurrence risk.
Approved indications
- Adjuvant chemotherapy for various solid tumors (specific indication depends on cancer type and clinical context)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Nausea and vomiting
- Myelosuppression
- Peripheral neuropathy
- Electrolyte abnormalities (hypomagnesemia, hypokalemia)
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin（adjuvant） CI brief — competitive landscape report
- Cisplatin（adjuvant） updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI